Tech

FDA Lifts MAGNITUDE-2 Hold; Enrollment Target 60

FDA has lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 IND for nexiguran ziclumeran (nex-z) in ATTRv-PN. Enrollment has been raised to about 60 patients, and the protocol now includes enhanced liver safety monitoring. The move reduces regulatory uncertainty and could accelerate topline data for MAGNITUDE-2.

📅 January 27, 2026
⏱️ 2 min read
FDA Lifts MAGNITUDE-2 Hold; Enrollment Target 60

Key Takeaways

  • FDA removed the clinical hold on MAGNITUDE-2 IND for nex-z, reducing regulatory uncertainty.
  • Enrollment target raised from ~50 to ~60 patients, increasing study power.
  • Primary endpoints are changes in mNIS and serum TTR levels; enhanced liver safety monitoring added.
  • Past holds in Oct 2025 due to Grade 4 liver enzymes and bilirubin signaling safety concerns.
  • NTLA stock rose about 9.5% to $15.28 after the news.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Intellia Therapeutics Inc. (NTLA)Biotechnology company developing gene-editing therapies
  • Nexiguran ziclumeran (nex-z)Investigational therapy candidate for ATTRv-PN in MAGNITUDE-2
  • FDA - U.S. Food and Drug AdministrationRegulatory agency lifting and imposing IND holds

MarketMoodz Analysis

Removing the MAGNITUDE-2 hold reduces regulatory uncertainty for Intellia’s ATTRx platform and could accelerate topline data generation, potentially boosting the stock's risk/reward. Near-term catalysts include the timing of readouts and alignment on MAGNITUDE's path forward as the program advances.

Historically, safety signals have driven volatility in gene-therapy programs; the Oct 2025 liver-safety concerns underscored the importance of rigorous monitoring and clear regulatory guidance. The Phase 1 data showing a 92% 24-month TTR reduction at higher doses underpin the therapeutic rationale for nex-z, but continued safety oversight remains a market-sensitive swing factor.

What to watch next: regulatory clarity across the MAGNITUDE program, updates to enrollment and safety milestones, and any readouts from MAGNITUDE-2 that could validate the uptick in enrollment and the program's trajectory.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial